（编辑 楚丽君） 证券日报网讯 1月6日，爱尔眼科在互动平台回答投资者提问时表示，"明眸远观福利"活动长期有效， 具体请参阅公司于2024年10月31日发布的《关于举办"上市十五年，回馈投资者"活动的公告》，可拨打 证券部电话0731-85136739，公司将协助联系落实。 ...

证券日报网讯 1月6日，三博脑科发布公告称，公司股票于2026年1月5日、1月6日，连续2个交易日内日 收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动的情形。经核实，公司前期披露的信息不存 在需要更正、补充之处；近期公共传媒未报道与公司相关且市场关注度较高的信息；近期公司经营情况 及内外部经营环境未发生重大变化。 （编辑 任世碧） ...

Core Viewpoint - Shantou City has been recognized for its healthcare capabilities with the inclusion of its General Medicine Department in the national clinical key specialty list, highlighting its leadership in medical services within the Chaoshan region [1] Group 1: Healthcare Development - The inclusion of Shantou City's General Medicine Department in the national clinical key specialty list signifies the city's growing influence as a provincial sub-center in healthcare services [1] - Shantou has established itself as a regional medical center, enhancing its position in the Shantou-Chaozhou-Jieyang urban agglomeration and providing advanced medical services to local residents [1][2] - The development of key specialties like oncology and general medicine strengthens the foundation of the provincial regional medical center, ensuring better healthcare access for the community [1] Group 2: Department Achievements - The General Medicine Department at Shantou City Central Hospital has a strong foundation, being one of the earliest and largest general medicine training bases in the region since its establishment in 2013 [2] - The department has developed an innovative "hospital-community-family" model for comprehensive healthcare management, facilitating seamless connections with community health service centers [2] - The department's focus on chronic disease management and preventive care has set a benchmark for improving grassroots healthcare services in the region [2] Group 3: Leadership and Research - The department is led by Wang Hao, a prominent figure in chronic disease research and a key talent in Guangdong's innovation plan, contributing significantly to national and provincial research projects [3] - Shantou City Central Hospital has achieved a breakthrough by having two national clinical key specialties, enhancing its reputation as a leading medical institution in the Chaoshan area [3] - The hospital aims to provide superior medical services to 15 million residents in Eastern Guangdong, aligning with the goals of provincial healthcare development [3]

格隆汇1月6日丨三博脑科(301293.SZ)公布股票交易异常波动公告，公司是以神经专科为特色的医疗服 务集团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产 品的研发、生产及销售，神经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影 响，敬请注意投资风险。 ...

Core Insights - The "Bet on China" top ten core asset portfolio launched by the company has shown strong performance, with a 3.6% increase on January 5, 2026, outperforming the Shanghai Composite Index and Hang Seng Index [1] - The portfolio has continued to rise, with a 2.65% increase on January 6, 2026, further exceeding the performance of major indices [1] - Year-to-date, the portfolio has accumulated a 6.14% increase, significantly surpassing the Shanghai Composite Index's 2.89% and Hang Seng Index's 4.29% [1] Company Performance - Alibaba-W (HK09988) saw a total increase of 7.0% over two trading days [1] - China Ping An (SH601318) increased by 5.8% [1] - WuXi AppTec (HK02268) rose by 4.4% [1] - Tencent Holdings (HK00700) increased by 4.3% [1] - Trip.com Group-S (HK09961) rose by 4.1% [1] - Oriental Fortune (SZ300059) increased by 2.5% [1] - Zhongji Xuchuang (SZ300308) rose by 2.2% [1] - Luoyang Molybdenum (SH603993) increased by 2.2% [1] - Gold ETF (SH518880) rose by 2.1% [1] - Wanhua Chemical (SH600309) increased by 0.9% [1] Future Outlook - The strong performance of core assets is attributed to the company's deep insights into industry trends and the economic pulse of China [2] - The company aims to continue identifying quality assets in the context of China's economic transformation, providing investors with precise asset allocation references [2] - The recent performance is seen as just the beginning of the value release of the core assets [2]

三博脑科于1月6日晚间发布股票交易异常波动公告。公司在公告中表示，其是以神经专科为特色的医疗 服务集团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。 该公司在公告中明确澄清，其目前不涉及脑机接口产品的研发、生产及销售业务。同时，公司指出，神 经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 作者：观察君 近期，脑机接口领域动态频发。美国企业家埃隆·马斯克于2025年12月31日通过社交平台发布消息，称 其旗下Neuralink计划于2026年启动脑机接口设备"大规模生产"，并推进几乎完全自动化的手术方案。此 外，由OpenAI首席执行官Sam Altman联合创立的脑机接口初创公司Merge Labs宣布将分拆为独立实 体，主攻基于超声波的非侵入式脑信号读取技术。 ...

交易行情显示，三博脑科于1月5日—6日连续两个交易日涨停，截至1月6日收盘，三博脑科报84.94元/ 股，涨幅为20.01%。 三博脑科表示，公司是以神经专科为特色的医疗服务集团，下属院区主要为患者提供以高精尖神经外科 为主的综合医疗服务。公司目前不涉及脑机接口产品的研发、生产及销售，神经调控技术带来的收入占 公司营业收入比重很小，对公司业绩基本没有影响。 北京商报讯（记者 丁宁）1月6日晚间，连续两个交易日涨停的三博脑科（301293）发布公告称，公司 股票于1月5日、1月6日，连续2个交易日内日收盘价格涨幅偏离值累计超过30%，根据《深圳证券交易 所交易规则》的规定，属于股票交易异常波动的情形。 ...

(本文来自第一财经) 三博脑科发布异动公告称，公司股票连续2个交易日内日收盘价格涨幅偏离值累计超过30%，属于股票 交易异常波动的情形。公司是以神经专科为特色的医疗服务集团，下属院区主要为患者提供以高精尖神 经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的研发、生产及销售，神经调控技术带来的 收入占公司营业收入比重很小，对公司业绩基本没有影响，敬请注意投资风险。 ...

智通财经APP讯，三博脑科(301293.SZ)公告称，公司股票于2026年1月5日、1月6日，连续2个交易日内 日收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动的情形。公司是以神经专科为特色的医疗 服务集团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口 产品的研发、生产及销售，神经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影 响。 ...

三博脑科股票交易异常波动公告，公司是以神经专科为特色的医疗服务集团，下属院区主要为患者提供 以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的研发、生产及销售，神经调控 技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响，敬请注意投资风险。 ...